Bluejay Diagnostics Q1 2026: net loss $1.9M, SYMON-II study at 680 of 750 patients

Bluejay Diagnostics, Inc.

Cash and equivalents $3.7M as of Mar 31, 2026; net loss $1.9M unchanged YoY.
SYMON-II pivotal study enrollment at ~680 patients toward target of 750.
Resolved manufacturing issues with Sanyoseiko; progressing toward analytical/clinical validation.
Continuing FDA 510(k) strategy for Symphony IL-6 test after validation activities.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.